Reckitt Benckiser agreed to pay up to $1.4 billion to resolve long-running civil and criminal investigations by the Department of Justice and the Federal Trade Commission into the sales and marketing of Suboxone Film, an opioid-addiction treatment, which is now sold by Indivior, its former pharmaceuticals unit.

The deal comes three months after federal prosecutors charged Indivior, which Reckitt spun off in 2014, with engaging in a multibillion-dollar fraudulent scheme to increase prescriptions of the medicine, which is dissolved in the mouth and also used to treat addiction to other narcotics.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy